- The relation between androgenetic thin hair diagnosed by trichoscope and benign prostatic hyperplasia. [Journal Article]
- JCJ Cosmet Dermatol 2018 Dec 05
- CONCLUSIONS: Androgenetic alopecia patients with thin hair diagnosed by trichoscopy are more prone to prostatic enlargement and its related symptoms. Androgenetic alopecia severity can be diagnosed by trichoscopy in addition to Hamilton-Norwood scale.
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata. [Journal Article]
- JEJ Eur Acad Dermatol Venereol 2018 Dec 06
- Alopecia areata (AA) is a common autoimmune disease driven by Th1 cytokines characterized by non-scarring hair loss.1,2 Mouse models have demonstrated that IFN-γ-producing NKG2D+ CD8+ cytotoxic T lym...
Alopecia areata (AA) is a common autoimmune disease driven by Th1 cytokines characterized by non-scarring hair loss.1,2 Mouse models have demonstrated that IFN-γ-producing NKG2D+ CD8+ cytotoxic T lymphocytes (CTLs) are essential for disease pathogenesis, along with JAK-STAT dependent cytokines IFN-γ and IL-15, which induce autoreactive T cell activation.1,3 This article is protected by copyright. All rights reserved.
- Patient Preferences Regarding Chemotherapy in Metastatic Breast Cancer-A Conjoint Analysis for Common Taxanes. [Journal Article]
- FOFront Oncol 2018; 8:535
- Background: The purpose of this investigation was to explore patient perception regarding the importance of efficacy, toxicity, and logistics in the choice of regimen of taxane-based chemotherapy (C...
Background: The purpose of this investigation was to explore patient perception regarding the importance of efficacy, toxicity, and logistics in the choice of regimen of taxane-based chemotherapy (CHT) for patients with metastatic breast cancer (MBC). Methods: This dual-center study analyzed data of 100 women diagnosed with MBC, who were asked for their preferences regarding chemotherapy by means of conjoint analysis. Included attributes were progression free survival (PFS), application form, time and frequency, need of premedication, risk of alopecia, fatigue, febrile neutropenia, and neuropathy. Furthermore, participants completed a questionnaire about their personal and medical history. Regression analyses were performed to identify factors that influence patient preference in terms of specific treatment choice. Results: Of 8 attributes, severe neutropenia was top priority for the majority of patients, followed by alopecia, neuropathy and PFS. When combining these patient preferences and the results of the questionnaire, patients' age as, well as, relationship status had significant impact on the importance of PFS. Moreover, longer travel time to the treatment center was significantly associated with preferences regarding PFS. Ranking by combination of respective part-worth values demonstrated nab-paclitaxel to be favored over paclitaxel and docetaxel. Conclusion: Side effects of CHT and PFS prove to be critical factors for patients affecting choice of treatment in MBC with severe neutropenia being top priority, followed by alopecia, neuropathy, and PFS. Age, commute time, and relationship status were identified as significant determinants of patient preference. Total utility calculation by combination of part-worth values ranked nab-paclitaxel as the most preferable taxane.
- Unusual Maculopapular Rash on the Scalp of a Patient with Mediterranean Spotted Fever. [Journal Article]
- MPMed Princ Pract 2018 Dec 03
- CONCLUSIONS: The rash on the scalp described in this report enriches our knowledge on the clinical characteristics of MSF.
- Protective Role of α2-Macroglobulin against Jaw Osteoradionecrosis in a Preclinical Rat Model. [Journal Article]
- JOJ Oral Pathol Med 2018 Dec 01
- CONCLUSIONS: A clinically translational model of jaw ORN was successfully established and the application of α2M prior to radiation protected the bone from being injured by the radiation, possibly related to oxidative stress. This article is protected by copyright. All rights reserved.
- Alopecia Areata and Poliosis: A Retrospective Analysis of 258 Cases. [Journal Article]
- JAJ Am Acad Dermatol 2018 Nov 28
- Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata. [Journal Article]
- JAJ Am Acad Dermatol 2018 Nov 28
- The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis. [Journal Article]
- COCutan Ocul Toxicol 2018 Dec 02; :1-17
- CONCLUSIONS: Our analysis of data has demonstrated that combined BRAF and MEK inhibitor-based treatment is associated with an increased risk of all-grade rash and a decreased risk of all-grade and high-grade HK, SP, alopecia, cSCC, HFS, and PR compared with single BRAF inhibitor alone in melanoma patients. Appropriate prevention and management are recommended.
- Treatment of canine sarcoptic mange with afoxolaner (NexGard®) and afoxolaner plus milbemycin oxime (NexGard Spectra®) chewable tablets: efficacy under field conditions in Portugal and Germany. [Journal Article]
- PParasite 2018; 25:63
- The efficacy of NexGard® and NexGard Spectra® against sarcoptic mange in dogs was evaluated in a clinical field study. Skin scrapings from dogs presenting signs suggestive of sarcoptic mange were exa...
The efficacy of NexGard® and NexGard Spectra® against sarcoptic mange in dogs was evaluated in a clinical field study. Skin scrapings from dogs presenting signs suggestive of sarcoptic mange were examined to confirm infestation. A total of 106 dogs were screened at eight sites in Portugal and Germany. In all, 80 dogs that had demonstrated ≥5 live Sarcoptes mites in five skin scrapings were enrolled, scored for specific clinical signs (pruritus; papules and crusts; alopecia), and allocated at random to receive either NexGard® or NexGard Spectra® twice, one month apart per label instructions. To determine efficacy, live Sarcoptes mites in five skin scrapings per dog were counted, and clinical signs were scored one month and two months after first treatment and compared to pre-treatment (baseline) values. Based on compliance, 65 dogs were determined to be evaluable cases at the end of the study. The efficacy, in terms of reduction of geometric mean live Sarcoptes mite counts, was 98.9% and 99.7% for NexGard®-treated (n = 38) and 99.6% and 100% for NexGard Spectra®-treated dogs (n = 27) at one month and two months after treatment initiation (p < 0.001, both treatments). Both treatments resulted in a significant improvement in pruritus, papules and crusts, and alopecia one month and two months after treatment initiation (p = 0.0001, both treatments). In conclusion, this field study confirms that both NexGard® and NexGard Spectra® administered twice one month apart provide an effective and safe treatment against sarcoptic mange in dogs.
New Search Next
- Randomized controlled trial on a PRP-like cosmetic, biomimetic peptides based, for the treatment of Alopecia Areata. [Journal Article]
- JDJ Dermatolog Treat 2018 Dec 04; :1-26
- Background Alopecia areata (AA) is a non-scarring auto-immune hair disorder. Recent researches explained the role of growth factors (GFs) in hair follicle cycling. The main reservoir of GFs are alpha...
Background Alopecia areata (AA) is a non-scarring auto-immune hair disorder. Recent researches explained the role of growth factors (GFs) in hair follicle cycling. The main reservoir of GFs are alpha-granules of platelets and novel procedures have been implemented aimed at collecting platelet-rich plasma (PRP). PRP has been safely implemented in many medical application and has also been successfully used as alternative cell-based therapies for the treatment of hair growth disorder, among which also AA. Objectives By mean of a randomized double-blinded, placebo and active-controlled, parallel group study we have studied the efficacy of a cosmetic product (named TR-M-PRP plus) comprising biomimetic peptides specific for hair growth mimicking PRP composition for the treatment of AA. Subjects were treated for three months end evaluated, at the end of the study and after one month of follow-up, as regards hair growth using SALT score. Results PRP-like topic produced a statistically significant (p < 0.001) clinical improvement in SALT score after 3 month of therapy, compared to baseline. Hair growth resulted further improved after 1 month of follow-up. Conclusions This clinical investigation suggest that the biotechnological designed PRP-like cosmetic could represent a valid and safer alternative to autologous PRP for the treatment of AA.